

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the shares in Alibaba Health Information Technology Limited.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS

GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS

On April 28, 2016, the Company granted 5,832,000 Options to 34 Grantees and 16,214,890 RSUs to 57 Grantees in accordance with the terms of the Share Award Scheme, subject to acceptance.

SHARE OPTIONS

On April 28, 2016, the Company granted 5,832,000 Options to 34 Grantees in accordance with the terms of the Share Award Scheme, subject to acceptance.

Details of the Grant

The details of the Options granted to the Grantees are as follows:

Date of Grant: April 28, 2016

Number of Grantees: 34

Total number of new Shares to be subscribed upon exercise of the Options granted: 5,832,000

Consideration for the grant: Nil

Exercise price of the Options granted: HK\$5.32 per Share

Validity period of the Options: The validity period of the Options shall be ten years from the Date of Grant and the Options shall lapse at the expiry of the validity period.

Vesting period: The Options granted shall vest in the Grantees on the vesting schedule set out in the table below:

Category of Grantees	Number of Grantees	Number of Options Granted	Vesting Schedule								
			Oct 10, 17	Jan 31, 18	Apr 30, 18	Oct 10, 18	Jan 31, 19	Apr 30, 19	Oct 10, 19	Jan 31, 20	Apr 30, 20
(A)	1	76,000	38,000	-	-	19,000	-	-	19,000	-	-
(B)	14	2,407,000	-	1,203,500	-	-	601,750	-	-	601,750	-
(C)	19	3,349,000	-	-	1,674,500	-	-	837,250	-	-	837,250

The Options granted are not subject to performance targets.

Exercise Price

The exercise price of the Options of HK\$5.32 per Share represents the highest of (i) the closing price of the Shares of HK\$5.32 per Share as stated in the daily quotation sheet issued by the Stock Exchange on the Date of Grant, (ii) the average closing price of the Shares of HK\$5.258 per Share as stated in the daily quotation sheets issued by the Stock Exchange for the five business days immediately preceding the Date of Grant, and (iii) the nominal value of each Share, which is HK\$0.01.

RESTRICTED SHARE UNITS

On April 28, 2016, the Company granted 16,214,890 RSUs to 57 Grantees in accordance with the terms of the Share Award Scheme, subject to acceptance. In accordance with the terms of the Share Award Scheme, the RSUs were granted to the Grantees under the following terms:

- each of the RSUs was granted for nil consideration;
- each of these RSUs to be granted to the Grantees represents the right to receive a Share on the date it vests;
- any Share to be issued upon vesting and settlement of a RSU will rank *pari passu* in all respects among themselves and with all the Shares in issue from time to time; and
- the RSUs granted are not subject to performance targets.

The RSUs granted shall vest in the Grantees on the vesting schedule set out in the table below:

Category of Grantees	Number of Grantees	Number of RSUs Granted	Number																
			Apr 30, 16	Jul 31, 16	Oct 10, 16	Jan 1, 17	Apr 30, 17	Jul 31, 17	Oct 10, 17	Jan 1, 18	Apr 30, 18	Jul 31, 18	Oct 10, 18	Jan 1, 19	Apr 30, 19	Jul 31, 19	Oct 10, 19	Jan 1, 20	Apr 30, 20
A	1	71,000	-	-	-	-	-	-	35,500	-	-	-	17,750	-	-	-	17,750	-	-
B	1	370,160	66,380	-	-	-	101,260	-	-	-	101,260	-	-	-	101,260	-	-	-	-
C	1	766,230	259,910	-	123,205	-	259,910	-	123,205	-	-	-	-	-	-	-	-	-	-
D	1	348,790	-	-	174,390	-	-	-	87,200	-	-	-	87,200	-	-	-	-	-	-
E	1	90,830	13,210	-	-	-	41,110	-	-	-	36,510	-	-	-	-	-	-	-	-
F	1	900,100	-	-	-	350,050	-	-	-	350,050	-	-	-	200,000	-	-	-	-	-
G	1	325,860	44,590	-	-	-	143,090	-	-	-	138,180	-	-	-	-	-	-	-	-
H	1	353,860	-	103,780	-	-	73,150	103,780	-	-	73,150	-	-	-	-	-	-	-	-
I	1	563,270	-	109,310	3,020	-	138,680	106,660	3,020	-	138,680	-	-	-	63,900	-	-	-	-
J	1	406,760	140,100	-	-	-	140,100	-	-	-	70,060	-	-	-	56,500	-	-	-	-
K	1	263,640	62,300	-	-	-	100,670	-	-	-	100,670	-	-	-	-	-	-	-	-
L	1	2,457,540	-	803,580	63,830	-	306,230	785,940	63,830	-	306,230	-	-	-	127,900	-	-	-	-
M	1	271,750	-	-	-	-	75,120	-	-	-	74,260	-	-	-	47,250	-	-	-	-
N	1	137,420	-	-	4,660	-	50,450	-	3,040	-	50,450	-	-	-	28,820	-	-	-	-
O	1	1,102,840	-	-	-	-	338,030	-	-	-	338,030	-	-	-	-	-	-	-	-
P	1	63,040	-	-	-	63,040	-	-	-	-	-	-	-	-	-	-	-	-	-
Q	1	617,840	-	-	112,370	-	176,350	-	76,210	-	176,350	-	-	-	76,560	-	-	-	-
R	1	32,000	-	-	-	-	11,000	-	-	-	11,000	-	-	-	10,000	-	-	-	-
S	1	450,000	-	-	-	-	110,700	-	-	-	120,500	-	-	-	43,000	-	-	-	-
T	1	287,000	-	-	-	-	-	-	-	-	143,500	-	-	-	71,750	-	-	-	71,750
U	1	395,000	-	-	-	-	80,900	-	-	97,100	80,900	-	-	-	39,000	-	-	-	-
V	1	271,000	-	-	-	-	-	-	-	-	135,500	-	-	-	67,750	-	-	-	67,750
W	1	109,000	-	-	-	-	-	-	-	-	54,500	-	-	-	27,250	-	-	-	27,250
X	1	378,400	-	-	47,600	-	180,500	-	47,700	-	81,400	-	-	-	21,200	-	-	-	-
Y	2	202,560	-	-	-	50,640	-	-	-	50,640	-	-	-	50,640	-	-	-	50,640	-
Z	14	2,248,000	-	-	-	-	-	-	-	1,124,000	-	-	-	562,000	-	-	-	562,000	-
AA	17	2,731,000	-	-	-	-	-	-	-	-	1,365,500	-	-	-	682,750	-	-	-	682,750
Total	57	16,214,890	1,088,390	1,104,570	529,075	560,830	2,327,250	1,084,280	439,705	1,621,790	3,596,630	-	104,950	812,640	1,464,890	-	17,750	612,640	849,500

Based on the closing price of HK\$5.32 per Share as quoted on the Stock Exchange on the Date of Grant, the market value of the RSUs granted to the Grantees amounts to approximately HK\$86.3 million.

GRANTEES

To the best of the knowledge of the Directors, none of the Grantees is a Director or a connected person of the Company.

DEFINITIONS

“Board”	the board of directors of the Company
“Company”	Alibaba Health Information Technology Limited (阿里健康信息技術有限公司), a company incorporated in Bermuda and listed on the Stock Exchange (Stock Code: 00241)
“connected person(s)”	has the same meaning as ascribed to it under the Listing Rules
“Date of Grant”	April 28, 2016
“Director(s)”	director(s) of the Company
“Grantees”	the employees of the Group whom were granted Options and/or RSUs in accordance with the Share Award Scheme on the Date of Grant, and who are independent of the Company and its connected persons
“HK\$”	the lawful currency of Hong Kong
“Hong Kong”	Hong Kong Special Administrative Region of the PRC
“Listing Rules”	Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“Option(s)”	option(s) to subscribe for or acquire Shares which is granted under the Share Award Scheme
“RSU(s)”	restricted share unit(s), being a contingent right to receive Shares which is awarded under the Share Award Scheme

“Share Award Scheme”	the share award scheme adopted by the Company at a special general meeting on November 24, 2014, the principal terms of which were set out on pages 10 to 20 of the Company’s circular dated October 31, 2014
“Shares”	fully paid ordinary shares with a nominal value of HK\$0.01 each in the share capital of the Company or, if there has been a sub-division, reduction, consolidation, reclassification or reconstruction of the share capital of the Company, the shares forming part of the ordinary share capital of the Company of such nominal amount as shall result from any such sub-division, reduction, consolidation, reclassification or reconstruction
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

By Order of the Board
Alibaba Health Information Technology Limited
WANG Lei
Chief Executive Officer and Executive Director

Hong Kong, April 28, 2016

As at the date of this announcement, the Board comprises nine directors, of which (i) two are executive Directors, namely Ms. CHEN Xiao Ying and Mr. WANG Lei; (ii) four are non-executive Directors, namely Mr. WU Yongming, Mr. TSAI Chung, Joseph, Ms. HUANG Aizhu and Mr. KANG Kai; and (iii) three are independent non-executive Directors, namely Mr. YAN Xuan, Mr. LUO Tong and Mr. WONG King On, Samuel.